Josefine Amalie Loft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josefine Amalie Loft has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Dam Nielsen
Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet
4 shared publications - Dina Leth Møller
Viro-Immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
3 shared publications - Allan Rasmussen
Department of Digestive Diseases, Transplantation and General Surgery Rigshospitalet, University of Copenhagen Copenhagen Denmark
2 shared publications - Caroline Anne Sabin
Institute for Global Health, University College London, London, UK
2 shared publications - Henning Bundgaard
Copenhagen University Hospital
2 shared publications - Kasper Iversen
Department of Cardiology, The Heart Centre, University Hospital Copenhagen, Copenhagen, Denmark
2 shared publications
Latest Publications
- Open Access
Incidence of Confirmed Influenza and Pneumococcal Infections and Vaccine Uptake Among Virologically Suppressed People Living with HIV
Background/Objectives: Influenza and Streptococcus pneumoniae infections are common vaccine-preventable diseases to which people living with HIV (PLWH) may be more susceptible. This study aims to investigate the incidence of confirmed influenza and pneumococcal infections, and to determine the incidence rate (IR) and factors associated with vaccine uptake in a population of virologically suppressed PLWH. Methods: We included 1031 virologically suppressed PLWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study. Data on infections and vaccinations between 2015 and 2020 were collected from nationwide registries. Incidence rates with 95% confidence intervals (CIs) of confirmed influenza and pneumococcal infections and vaccine uptake were calculated, and predictors of vaccine uptake were explored using logistic regression. Results: The IR of influenza showed variation from year to year and ranged between 0 (95% CI: 0.0, 7.6) and 18.0 (95% CI: 8.2, 34.1) per 1000 person-years at risk with an overall IR of 8.4 per 1000 person-years at risk (95% CI: 5.4, 12.3). The overall IR of pneumococcal infections was 5.5 per 1000 person-years at risk (95% CI: 3.9, 7.5). Among PLWH, 53.2% were influenza-vaccinated at least once, 72.3% and 22.6% of PLWH were vaccinated at least twice and in all six seasons, respectively, while 31% had at least one pneumococcal vaccine. Previous pneumonia or bronchitis, higher body mass index, use of drugs to treat heart conditions, and longer time with HIV were independently associated with vaccine uptake. Conclusions: We found high incidences of confirmed influenza and pneumococcal infections in virologically suppressed PLWH, but vaccine uptake was below recommendations, highlighting the need for improved vaccination counseling.
Open AccessIncidence of Confirmed Influenza and Pneumococcal Infections and Vaccine Uptake Among Virologically Suppressed People Living with HIV
Background/Objectives: Influenza and Streptococcus pneumoniae infections are common vaccine-preventable diseases to which people living with HIV (PLWH) may be more susceptible. This study aims to investigate the incidence of confirmed influenza and pneumococcal infections, and to determine the incidence rate (IR) and factors associated with vaccine uptake in a population of virologically suppressed PLWH. Methods: We included 1031 virologically suppressed PLWH from the Copenhagen Comorbidity in HIV Infection (COCOMO) study. Data on infections and vaccinations between 2015 and 2020 were collected from nationwide registries. Incidence rates with 95% confidence intervals (CIs) of confirmed influenza and pneumococcal infections and vaccine uptake were calculated, and predictors of vaccine uptake were explored using logistic regression. Results: The IR of influenza showed variation from year to year and ranged between 0 (95% CI: 0.0, 7.6) and 18.0 (95% CI: 8.2, 34.1) per 1000 person-years at risk with an overall IR of 8.4 per 1000 person-years at risk (95% CI: 5.4, 12.3). The overall IR of pneumococcal infections was 5.5 per 1000 person-years at risk (95% CI: 3.9, 7.5). Among PLWH, 53.2% were influenza-vaccinated at least once, 72.3% and 22.6% of PLWH were vaccinated at least twice and in all six seasons, respectively, while 31% had at least one pneumococcal vaccine. Previous pneumonia or bronchitis, higher body mass index, use of drugs to treat heart conditions, and longer time with HIV were independently associated with vaccine uptake. Conclusions: We found high incidences of confirmed influenza and pneumococcal infections in virologically suppressed PLWH, but vaccine uptake was below recommendations, highlighting the need for improved vaccination counseling.
- Open Access
Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection
Background: Solid organ transplant (SOT) recipients are at risk of severe COVID-19. Vaccination is an important preventive measure but may have side effects, including decreased leukocyte counts. We aimed to describe the prevalence and relative incidence of decreased leukocyte counts and changes in leukocyte counts before and after SARS-CoV-2 mRNA vaccination and SARS-CoV-2 infection in SOT recipients. Methods: Changes in leukocyte counts from before to after each vaccine dose were investigated using linear mixed models. We determined the prevalence of decreased leukocyte counts before and after each vaccine dose and before and after SARS-CoV-2 infection. Self-controlled case series analysis was used to investigate whether the period after either vaccination or infection was associated with risk of decreased leukocyte count. Results: We included 228 adult kidney, lung, and liver transplant recipients. Prior to the first vaccine dose, the mean leukocyte count was 7.3 × 109 cells/L (95% CI 6.9–7.6). Both the leukocyte counts, and the prevalence of decreased leukocyte counts remained unchanged from before to after vaccination regardless of the number of vaccine doses provided. There was no association between vaccination and decreased leukocyte counts (incidence rate ratio (IRR): 0.6; 95% CI: 0.2–2.1; p = 0.461). In contrast, SARS-CoV-2 infection was associated with increased risk of a decreased leukocyte count (IRR: 7.1; 95% CI: 2.8–18.1; p < 0.001). Conclusions: SARS-CoV-2 mRNA vaccination was not associated with risk of decreased leukocyte count and did not affect the prevalence of decreased leukocyte counts in SOT recipients. In contrast, SARS-CoV-2 infection was associated with a higher risk of a decreased leukocyte count.
Open AccessLeukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection
Background: Solid organ transplant (SOT) recipients are at risk of severe COVID-19. Vaccination is an important preventive measure but may have side effects, including decreased leukocyte counts. We aimed to describe the prevalence and relative incidence of decreased leukocyte counts and changes in leukocyte counts before and after SARS-CoV-2 mRNA vaccination and SARS-CoV-2 infection in SOT recipients. Methods: Changes in leukocyte counts from before to after each vaccine dose were investigated using linear mixed models. We determined the prevalence of decreased leukocyte counts before and after each vaccine dose and before and after SARS-CoV-2 infection. Self-controlled case series analysis was used to investigate whether the period after either vaccination or infection was associated with risk of decreased leukocyte count. Results: We included 228 adult kidney, lung, and liver transplant recipients. Prior to the first vaccine dose, the mean leukocyte count was 7.3 × 109 cells/L (95% CI 6.9–7.6). Both the leukocyte counts, and the prevalence of decreased leukocyte counts remained unchanged from before to after vaccination regardless of the number of vaccine doses provided. There was no association between vaccination and decreased leukocyte counts (incidence rate ratio (IRR): 0.6; 95% CI: 0.2–2.1; p = 0.461). In contrast, SARS-CoV-2 infection was associated with increased risk of a decreased leukocyte count (IRR: 7.1; 95% CI: 2.8–18.1; p < 0.001). Conclusions: SARS-CoV-2 mRNA vaccination was not associated with risk of decreased leukocyte count and did not affect the prevalence of decreased leukocyte counts in SOT recipients. In contrast, SARS-CoV-2 infection was associated with a higher risk of a decreased leukocyte count.
- Open Access
The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT recipients previously vaccinated with at least three doses of BNT162b2, we investigated humoral responses to BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using an in-house ELISA. Linear mixed models were fitted to investigate the change in the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG after vaccination in participants with intervals of more or less than six months between the last two doses of vaccine. We included 107 SOT recipients vaccinated with a BNT162b2 vaccine. In participants with an interval of more than six months between the last two vaccine doses, we found a 1.34-fold change in GMC per month (95% CI 1.25–1.44), while we found a 1.09-fold change in GMC per month (95% CI 0.89–1.34) in participants with an interval of less than six months between the last two vaccine doses, resulting in a rate ratio of 0.82 (95% CI 0.66 to 1.01, p = 0.063). In conclusion, the administration of identical COVID-19 mRNA vaccine boosters within six months to SOT recipients may result in limited humoral immunogenicity of the last dose.
Open AccessThe Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
As solid organ transplant (SOT) recipients remain at risk of severe outcomes after SARS-CoV-2 infections, vaccination continues to be an important preventive measure. In SOT recipients previously vaccinated with at least three doses of BNT162b2, we investigated humoral responses to BNT162b2 booster doses. Anti-SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) was measured using an in-house ELISA. Linear mixed models were fitted to investigate the change in the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG after vaccination in participants with intervals of more or less than six months between the last two doses of vaccine. We included 107 SOT recipients vaccinated with a BNT162b2 vaccine. In participants with an interval of more than six months between the last two vaccine doses, we found a 1.34-fold change in GMC per month (95% CI 1.25–1.44), while we found a 1.09-fold change in GMC per month (95% CI 0.89–1.34) in participants with an interval of less than six months between the last two vaccine doses, resulting in a rate ratio of 0.82 (95% CI 0.66 to 1.01, p = 0.063). In conclusion, the administration of identical COVID-19 mRNA vaccine boosters within six months to SOT recipients may result in limited humoral immunogenicity of the last dose.
- Open Access
- 8 April 2024
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 186, 1
Maribavir for treatment of cytomegalovirus infection in a liver-transplanted patient
- 8 April 2024
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 186, 1
Open AccessMaribavir for treatment of cytomegalovirus infection in a liver-transplanted patient